Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | UTRN | P46939 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633786 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL13633895 | 0.80 | KDM4E (0.44) | ALDH1A1KDM4EHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL13633873 | 0.79 | MAPT (0.39) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL13633783 | 0.76 | PPARG (0.43) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL7496613 | 0.73 | KDM4E (0.55) | ALDH1A1KDM4EHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL8813501 | 0.69 | KDM4E (0.50) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL5534902 | 0.68 | KDM4E (0.59) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL13633894 | 0.68 | IKBKB (0.55) | CYP2A6 | |
| SCHEMBL144429 | 0.68 | CYP2A6 (0.45) | ALDH1A1KDM4EHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL9193008 | 0.66 | CYP2A6 (0.50) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | ALDH1A1 1255/4885KDM4E 4614/4885HPGD 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.